EWA
TBPH

EverSource Wealth Advisors’s Theravance Biopharma TBPH Stock Holding History

EverSource Wealth Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6K Sell
153
-699
-82% -$11.6K ﹤0.01% 3612
2026
Q1 		$13.8K Buy
852
+119
+16% +$2.1K ﹤0.01% 2742
2025
Q4 		$13.7K Buy
733
+272
+59% +$4.51K ﹤0.01% 2630
2025
Q3 		$6.73K Buy
461
+173
+60% +$2.19K ﹤0.01% 3014
2025
Q2 		$3.18K Buy
288
+246
+586% +$2.39K ﹤0.01% 3332
2025
Q1 		$375 Sell
42
-38
-48% -$354 ﹤0.01% 3548
2024
Q4 		$752 Buy
+80
New +$728 ﹤0.01% 3063

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

EverSource Wealth Advisors's TBPH Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Theravance Biopharma (TBPH) stake by 82% in Q2 2026, selling an estimated $11.6K and leaving 153 shares worth $2.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3612.

EverSource Wealth Advisors first reported a position in TBPH in Q4 2024 and has held it in 7 quarters since. The position peaked at $13.8K in Q1 2026. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • EverSource Wealth Advisors held 153 shares of Theravance Biopharma worth $2.6K as of Q2 2026.
  • EverSource Wealth Advisors sold 699 Theravance Biopharma shares in Q2 2026, an estimated $11.6K.
  • Theravance Biopharma made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3612 holding.
  • EverSource Wealth Advisors first reported a position in Theravance Biopharma in Q4 2024 and has held it in 7 quarters since.
  • EverSource Wealth Advisors's Theravance Biopharma position peaked at $13.8K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.